...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European respiratory review >Update on recent key publications in lung oncology: picking up speed
【24h】

Update on recent key publications in lung oncology: picking up speed

机译：肺肿瘤近期关键出版物的更新：拾取速度

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction As incidence rates for lung cancer are still very high and lung cancer remains the most deadly cancer since the turn of the millennium, efforts have been made to find new approaches in cancer research. This systematic review highlights how therapeutic options were extended and how the development of new drugs has picked up speed during the last 20?years. Methods A systematic search was performed in PubMed, Cochrane Library and the European Union Trial Register and 443 records were identified. Our inclusion criteria constituted completed phase I, II and III studies investigating drugs approved by the European Medicines Agency (EMA). Overall, 127 articles were analysed. Results During the 5?year interval from 2015 to 2020, significantly more drugs were approved after phase III, and occasionally after phase II, trials than between 2000 and 2005 (p=0.002). Furthermore, there was a significant time difference (p=0.00001) indicating an increasingly briefer time interval between the publication of phase I and phase III results in the last few years. Discussion Due to novel therapeutic approaches, numerous new drugs in lung oncology were approved. This has improved symptoms and prognoses in patients with advanced lung cancer. However, faster approval could make it difficult to scrutinise new options regarding safety and efficacy with sufficient diligence.
机译：由于肺癌的发病率仍然非常高，肺癌仍然是千年之后最具致命的癌症，因此已经努力寻找癌症研究的新方法。这种系统综述凸显了如何延长治疗选择以及如何在过去的20年内开发新药的发展。方法在PubMed，Cochrane库和欧盟试验登记册中进行系统检索，并确定了443条记录。我们的纳入标准构成了已完成的I，II和III研究调查欧洲药物署（EMA）批准的药物。总的来说，分析了127篇文章。结果在5？从2015年到2020年的时间间隔，在第III期后批准了更多的药物，偶尔在2000年至2005年之间试验（P = 0.002）。此外，存在显着的时间差（p = 0.00001），表明在过去几年中，III阶段发布和III期结果之间的日益推进的时间间隔。由于新的治疗方法，肺部肿瘤学的许多新药被批准。这具有改善肺癌患者的症状和预期。但是，更快的批准可能使得难以审查有关充分勤奋的安全性和疗效的新选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号